During Tuesday’s Morning trade, Shares of Metlife Inc (NYSE:MET), lost -0.95% to $50.18.
As part of the MetLife BWF World Super series sponsored by MetLife, Inc., the #1 US life insurer^, YONEX-SUNRISE Hong Kong Open 2015 came to a memorable close yesterday at the Hong Kong Coliseum, with Malaysia’s Lee Chong Wei and Spain’s Carolina Marin emerging singles champions. The last time Lee took home the men’s singles championship in Hong Kong was in 2013.
The six-day tournament, which offers total prize money of USD350,000, is the Hong Kong stop of the BWF World Super series. Inaugurated in 2007, the BWF World Superseries comprises 12 tournaments, attracting the top 32 world-ranked players in singles and doubles. With its title sponsorship of this spectacular international event since 2014, MetLife has shown continued dedication to fulfilling its corporate social responsibility by fostering a healthy community globally.
Mr. Lennard Yong, Chief Executive Officer of MetLife Hong Kong*, attended the finals yesterday. “MetLife and BWF have partnered across the world with the shared mission to enhance diversity and health and wellness,” he said. “Through extending our global partnership to Hong Kong, we hope to engage and encourage the local community to build interest in sports and healthy living, as we continue to commit ourselves to realizing our brand promise to assist people pursue more from life.”
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
Shares of Sanchez Energy Corp (NYSE:SN), inclined 7.33% to $4.83, during its current trading session.
Moments ago, Trader’s Choice released new research updates concerning several important developing situations counting the following equities: Regulus Therapeutics Inc. (RGLS), Marilynjean Interactive Inc. (MJMI), Ova Science Inc (OVAS) and Sanchez Energy Corp. (SN). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Highlights from recently’s reports comprise:
On Thursday, November 19, 2015, the NASDAQ Composite ended at 5,073.64, down 0.03%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 17,732.75, and the S&P 500 closed at 2,081.24, down 0.11%.
- Regulus Therapeutics Inc.’s stock reduced by 4.41% to close Thursday’s session at USD 9.33. The company’s shares fluctuated in the range of USD 9.16 and USD 9.90 in trade during the day. A total of 0.41 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.62 million shares and was below its 52-week average volume of 0.70 million shares. Over the last three days Regulus Therapeutics Inc.’s shares have advanced 0.54% and in the past one week it has moved up 0.97%. Furthermore, over the last three months, the stock has gained 35.02% while in the past six months; the shares have shed 26.82%. The shares are trading above their 20-day and 50-day simple moving average by 13.4% and 20.06% respectively. However, the shares are trading 20.58% below their 200-day simple moving average. Additionally, the stock is trading at a price to book ratio of 3.86.
- Marilynjean Interactive Inc.’s stock added 11.11% to close Thursday’s session at USD 2.00. The company’s shares oscillated between USD 1.80 and USD 2.08 in trade during the day, marking a new 52-week high. The stock has a 52-week low of USD 0.10. The stock recorded a trading volume of 0.05 million shares, which was below its 50-day daily average volume of 0.11 million shares. Over the last five days, Marilynjean Interactive Inc.’s shares have declined by 24.24% whereas in the past one month, it has gained a momentum of 48.15%. In addition, over the last three months, the stock has gained 875.61% and year to date, the shares have picked up 700.00%. The company has returned 952.63% in the last year on a compounded total return basis. The company has a market cap of USD 389.06 million.
- OvaScience Inc.’s stock declined 0.64% to close Thursday’s session at USD 10.93. The share price vacillated between USD 10.75 and USD 11.13 during the day. The stock recorded a trading volume of 0.25 million shares, which was below its 50-day daily average volume of 0.68 million shares and below its 52-week average volume of 0.67 million shares. Over the last three days OvaScience Inc.’s shares have advanced 3.70% and in the past one week it has moved up 9.96%. Moreover, in the last six months, the stock has lost 64.90% and year to date, the shares have shed 75.28%. The shares of the company are trading below their 20-day and 50-day simple moving averages by 12.29% and 18.85% respectively. Additionally, OvaScience Inc.’s stock trades at a price to book ratio of 2.09 and has a Relative Strength Index of 37.99.
Sanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition, exploration, and development of unconventional oil and natural gas resources in the onshore U.S. Gulf Coast.
Finally, Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL), lost - 3.72%, and is now trading at $5.78.
Anavex Life Sciences Corp., declared the presentation of preclinical epilepsy data at the forthcoming American Epilepsy Society Annual Meeting on Monday, December 7, 2015 at 8:00 a.m. - 2:00 p.m. in Philadelphia, PA Convention Center, Hall A, 200 Level.
“ANAVEX 2-73 demonstrated convincing data in three well-established and predictive preclinical anti-seizure models with potentially more favorable side effect profile than presently marketed epilepsy drugs,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The cognitive-enhancing features of ANAVEX 2-73 might be a differentiating factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications. With recent data from the Phase 2a trial for ANAVEX 2-73, the Company is encouraged to continue exploring this additional indication.”
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates comprise ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease.